Pembrolizumab, an immune checkpoint inhibitor, has been approved by the US Food and Drug Administration for the treatment of ...

Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in ...

Douglas Adkins, MD, discusses future directions of the KEYNOTE-689 trial of pembrolizumab in head and neck cancer following the agent's FDA approval.

The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

The recent experience of Chinese biotech companies in developing their own drug candidates and inking deals with larger ...

DelveInsight’s Anaplastic Thyroid Cancer Pipeline report depicts a robust space with 8+ active players working to develop 8+ ...

Cancer plasticity allows tumor cells to change their identity, evade therapies, and adapt to environmental pressures, contributing to treatment resistance and metastasis. New research is targeting ...

TEL AVIV, Israel and SHANGHAI, China I June 16, 2025 I Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Shanghai Fosun Pharmaceutical (Group) ...